Drug Trial Radar · NCT04638751
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
5,000
Planned (sponsor's estimate)
Start
Jul 1, 2022
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Persephone BiosciencesIndustry
- Sponsor type
- Industry
- First posted
- Nov 20, 2020
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
ARGONAUT is a longitudinal, prospective, observational study that will enroll up to 5,000 advanced-stage cancer patients of diverse racial backgrounds to collect data used to develop precision microbiome medicines and for the identification of clinically actionable cancer-specific biomarkers to guide therapeutic decisions. Four types of solid tumor cancers will be profiled including non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), colorectal cancer (CRC) and pancreatic cancer. Healthy control subjects without a cancer diagnosis will also be studied, comprised of individuals at high risk for CRC and healthy individuals at low risk for CRC. Risk assessment will be based on family history or past neoplastic findings during CRC screening. Data collected from this study will be used to develop the most effective new therapies, via microbiome optimization, all to the benefit of patients and the physicians treating them. Stool and blood samples will be collected longitudinally and analyzed to determine the impact of gut microbiome composition and function on the immune system and efficacy of the treatment. Currently enrolling the CRC, high risk, and low risk cohorts. Subjects who meet the entry criteria will provide up to 5 samples each of blood and stool over a 2-year period. Approximately 10%-20% of the subjects will provide colon tissue samples, either from research biopsies during Standard of Care (SOC) screening colonoscopy or retained surgical tissue from colectomy. Electronic health records will be obtained at various times for up to 8 years, to collect tumor imaging results and any other updated medical data, with no additional samples collected. In select cases, stool and blood samples will be collected beyond 2 years.
Conditions
- Non-small Cell Lung Cancer
- Colorectal Cancer
- Triple Negative Breast Cancer
- Pancreas Cancer
Interventions
ImmunotherapyDrug
Checkpoint inhibitor
ChemotherapyDrug
Any form of chemotherapy
CRC surgical resectionProcedure
Surgical resection to remove colorectal cancer
ColonoscopyProcedure
Standard-of-care colonoscopy for CRC screening
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine whether the microbiome composition can predict progression-free survivalTime frame: 6-12 months
- Determine whether the microbiome composition can predict risk for colorectal cancerTime frame: 2-8 years
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Knowledge Research Center
Orange, California
SDG Clinical Research, Inc
San Diego, California
Persephone Biosciences, Inc.
San Diego, California
L&A Morales Healthcare, Inc
Miami, Florida
Baton Rouge General Medical Center
Baton Rouge, Louisiana
University Medical Center New Orleans
New Orleans, Louisiana
Mid-Hudson Medical Research
New Windsor, New York
Kroger Health, The Little Clinic
Cincinnati, Ohio
Southwest Family Medicine Associates
Dallas, Texas
Biopharma Informatic
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.